Packard Kathleen A, Khan Manzoor M
Department of Pharm Sciences, Creighton University, Omaha, NE 68178, USA.
Int Immunopharmacol. 2003 Jul;3(7):909-20. doi: 10.1016/S1567-5769(02)00235-7.
Atopic asthma is a chronic inflammatory disorder of the airways where upon exposure to allergens, the body mounts an immune response. This disease is associated with an increase in the number of Th2 (T helper type 2) cells and Th2 cytokines and a decrease in the number of Th1 (T helper type 1) cells and Th1 cytokines. Histamine plays an important role in the pathogenesis of atopic asthma through differential regulation of T helper lymphocytes. Histamine enhances the secretion of Th2 cytokines such as IL-4 (interleukin-4), IL-5, IL-10 and IL-13 and inhibits the production of Th1 cytokines IL-2 and IFNgamma (interferon-gamma) and monokine IL-12. It has been shown that histamine can modulate the cytokine network through upregulation of PGE(2) (prostaglandin E(2)) and NO (nitric oxide). Histamine also affects cytokine production via H2 receptors and through the activation of PKA (protein kinase A). We have also demonstrated that the Jak-STAT (Janus kinase-signal transducers and activators of transcription) pathway is involved in histamine-mediated regulation of Th2 cytokines IL-5, IL-10, IL-13 and Th1 cytokine IFNgamma. While standard treatment of asthma consists of beta-receptor agonists and inhaled corticosteroids, the elucidation of histamine's control over the cytokine network and the Th1/Th2 balance provides a basis for the potential use of antihistamines in the prevention and treatment of atopic asthma. Several other anti-allergic agents to modulate the Th1/Th2 balance are under current investigation based on this paradigm. These include cytokines, cytokine antagonists, anti-IgE, and vaccinations. As more advances are made in our understanding of histamine and its control over the Th1/Th2 balance, the use of new therapeutic targets such as these will play a prominent role in disease management.
特应性哮喘是一种气道慢性炎症性疾病,在接触过敏原后,机体产生免疫反应。这种疾病与Th2(辅助性T细胞2型)细胞和Th2细胞因子数量增加以及Th1(辅助性T细胞1型)细胞和Th1细胞因子数量减少有关。组胺通过对辅助性T淋巴细胞的差异调节在特应性哮喘的发病机制中起重要作用。组胺增强Th2细胞因子如白细胞介素-4(IL-4)、IL-5、IL-10和IL-13的分泌,并抑制Th1细胞因子IL-2和干扰素-γ(IFNγ)以及单核因子IL-12的产生。已经表明,组胺可通过上调前列腺素E2(PGE2)和一氧化氮(NO)来调节细胞因子网络。组胺还通过H2受体并通过蛋白激酶A(PKA)的激活影响细胞因子的产生。我们还证明,Janus激酶-信号转导子和转录激活子(Jak-STAT)途径参与组胺介导的对Th2细胞因子IL-5、IL-10、IL-13和Th1细胞因子IFNγ的调节。虽然哮喘的标准治疗包括β受体激动剂和吸入性糖皮质激素,但对组胺对细胞因子网络和Th1/Th2平衡的控制的阐明为抗组胺药在预防和治疗特应性哮喘中的潜在应用提供了基础。基于这一模式,目前正在研究其他几种调节Th1/Th2平衡的抗过敏药物。这些药物包括细胞因子、细胞因子拮抗剂、抗IgE和疫苗接种。随着我们对组胺及其对Th1/Th2平衡的控制的理解取得更多进展,使用这些新的治疗靶点将在疾病管理中发挥重要作用。